MEXICO CITY.- The efficiency of a new pharmacy to combat an illness and more health. financial markets and the economy are also moving. This is the case of the notice that the efficacy of the plitidepsin is mentioned.
The Spanish company PharmaMar developed the pharmaceutical drug, confirmed by the prestigious science magazine Science as a “potent” alternative to the SARS-CoV-2, which has recently reduced the covid-19 viral load by up to 99 percent.
As of this notice, only PharmaMar has more than 21.1% in the ball, also IBEX 35, the main index bursatil of reference in the Spanish ball, dio a jump of .86% on March day.
Movement in the ball
PharmaMar’s titles were released at 21.14%, up to € 106.3, despite the fact that the ‘Science’ science magazine has confirmed the “potent” activity of plitidepsin in front of SARS-CoV-2. In the case of different animal models of infection by SARS-CoV-2, the test demonstrates the reduction of viral replication, which results in a 99% reduction in viral cargoes in the pulmonary animals treated with plididepsin.
“We believe that our positive data and the initial results of the PharmaMar clinical trial suggest that plitidepsina should be considered seriously in order to increase the clinical trials for the treatment of Covid-19”, states the trial presented by the pharmaceutical.
With information from Europa Press.
We can also learn:
Biden planea buys more than 100 million covid-19 vacancies
Helaas para volar: FMI projects recovery of 4.3% of GDP in Mexico
Boris Johnson accepted responsibility for crisis de covid-19 and Reino Unido